Roberto Infante (Italy)
Fondazione Mondino - Istituto Neurologico Nazionale IRCCS Stroke UnitAuthor Of 1 Presentation
EFFECTS OF SUBTHALAMIC DEEP BRAIN STIMULATION ON NEUROPSYCHIATRIC FLUCTUATIONS IN PATIENTS WITH PARKINSON’S DISEASE (PSYCHOSTIM STUDY)
- Roberto Infante (Italy)
Abstract
Background and Aims:
Neuropsychiatric Fluctuations (NPF) are frequent and disabling non-motor symptoms of advanced Parkinson’s Disease (PD). Little is known about the effects of bilateral subthalamic deep brain stimulation (STN-DBS) on NPF. We aimed at evaluating the effects of STN DBS on acute NPF using a dedicated scale, the Neuropsychiatric Fluctuation Scale (NFS). NFS combines items derived from various neuropsychiatric scales, in a simple, motor phase-dependant score (from -30 to +30 points).
Methods:
31 PD patients treated with STN-DBS received preoperative and postoperative (at 1 year after surgery) motor and non-motor assessments. The MDS-UPRDS total and sub-scores, levodopa equivalent daily dose (LEDD), and neuropsychological scales, including the NFS, were administrated in four conditions: preoperative “OFF-Med” and “ON-Med”, postoperative “OFF-Med/ON-Stim” and “ON-Med/ON-Stim”. Statistical analysis was realised with T-Student test and “post-hoc” confirmation (Wilcoxon and Spearman).
Results:
Mean postoperative “OFF-Med” NFS score significantly improved compared to the preoperative one (-14.4 vs -7.1 points; +49.3%; p=0.0003.), whereas “ON-Med” NFS score showed slight deterioration (+16.4 vs +13.8 points; -15.9%; p=0.48). NFS postoperative modifications did not correlate with the improvement of the MDS-UPDRS III or LEDD decrease. Conversely, postoperative decrease of the MDS-UPRDS II score correlated with the corresponding “OFF-Med” NFS score (p=0.019), but not with “ON-Med” NFS score (p=0.77).
Conclusions:
At 1-year follow-up, STN-DBS significantly improved NPF in the “OFF-Med” condition. This improvement was unrelated with the improvement of motor signs or medication reduction. The use of dedicated instruments (such as the NFS) appears to be very useful to monitor the impact of therapies in PD patients with non-motor fluctuations.
Presenter of 1 Presentation
EFFECTS OF SUBTHALAMIC DEEP BRAIN STIMULATION ON NEUROPSYCHIATRIC FLUCTUATIONS IN PATIENTS WITH PARKINSON’S DISEASE (PSYCHOSTIM STUDY)
- Roberto Infante (Italy)
Abstract
Background and Aims:
Neuropsychiatric Fluctuations (NPF) are frequent and disabling non-motor symptoms of advanced Parkinson’s Disease (PD). Little is known about the effects of bilateral subthalamic deep brain stimulation (STN-DBS) on NPF. We aimed at evaluating the effects of STN DBS on acute NPF using a dedicated scale, the Neuropsychiatric Fluctuation Scale (NFS). NFS combines items derived from various neuropsychiatric scales, in a simple, motor phase-dependant score (from -30 to +30 points).
Methods:
31 PD patients treated with STN-DBS received preoperative and postoperative (at 1 year after surgery) motor and non-motor assessments. The MDS-UPRDS total and sub-scores, levodopa equivalent daily dose (LEDD), and neuropsychological scales, including the NFS, were administrated in four conditions: preoperative “OFF-Med” and “ON-Med”, postoperative “OFF-Med/ON-Stim” and “ON-Med/ON-Stim”. Statistical analysis was realised with T-Student test and “post-hoc” confirmation (Wilcoxon and Spearman).
Results:
Mean postoperative “OFF-Med” NFS score significantly improved compared to the preoperative one (-14.4 vs -7.1 points; +49.3%; p=0.0003.), whereas “ON-Med” NFS score showed slight deterioration (+16.4 vs +13.8 points; -15.9%; p=0.48). NFS postoperative modifications did not correlate with the improvement of the MDS-UPDRS III or LEDD decrease. Conversely, postoperative decrease of the MDS-UPRDS II score correlated with the corresponding “OFF-Med” NFS score (p=0.019), but not with “ON-Med” NFS score (p=0.77).
Conclusions:
At 1-year follow-up, STN-DBS significantly improved NPF in the “OFF-Med” condition. This improvement was unrelated with the improvement of motor signs or medication reduction. The use of dedicated instruments (such as the NFS) appears to be very useful to monitor the impact of therapies in PD patients with non-motor fluctuations.